Raison and colleagues15 demonstrated the symptom-specific effectiveness of the tumor necrosis factor α inhibitor infliximab for suicidality (among 4 other symptoms) in patients with MD with high CRP levels before treatment. This evidence concerns the gene CRP and Menkes disease.